FRG Family Wealth Advisors LLC Has $6.40 Million Stake in Eli Lilly and Company (NYSE:LLY)

FRG Family Wealth Advisors LLC cut its holdings in Eli Lilly and Company (NYSE:LLY) by 5.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 8,287 shares of the company’s stock after selling 458 shares during the quarter. Eli Lilly and Company comprises 1.2% of FRG Family Wealth Advisors LLC’s portfolio, making the stock its 20th largest position. FRG Family Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $6,398,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Accredited Investors Inc. increased its stake in Eli Lilly and Company by 1.3% in the 4th quarter. Accredited Investors Inc. now owns 3,246 shares of the company’s stock valued at $2,506,000 after buying an additional 43 shares during the last quarter. Kennedy Capital Management LLC increased its stake in shares of Eli Lilly and Company by 17.0% during the 4th quarter. Kennedy Capital Management LLC now owns 41,351 shares of the company’s stock worth $31,923,000 after purchasing an additional 6,011 shares during the last quarter. Treasurer of the State of North Carolina grew its stake in Eli Lilly and Company by 1.0% in the 4th quarter. Treasurer of the State of North Carolina now owns 386,386 shares of the company’s stock valued at $298,290,000 after buying an additional 3,915 shares during the last quarter. Bank of Hawaii grew its stake in Eli Lilly and Company by 4.0% in the 4th quarter. Bank of Hawaii now owns 9,612 shares of the company’s stock valued at $7,420,000 after buying an additional 374 shares during the last quarter. Finally, Phoenix Financial Ltd. boosted its holdings in Eli Lilly and Company by 12.4% in the 4th quarter. Phoenix Financial Ltd. now owns 19,037 shares of the company’s stock valued at $14,697,000 after purchasing an additional 2,096 shares during the period. 82.53% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm’s stock in a transaction dated Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $737.00 on Thursday. The firm has a 50 day moving average of $840.79 and a 200-day moving average of $826.23. The company has a current ratio of 1.15, a quick ratio of 0.97 and a debt-to-equity ratio of 2.00. Eli Lilly and Company has a 12 month low of $677.09 and a 12 month high of $972.53. The firm has a market capitalization of $698.80 billion, a P/E ratio of 62.94, a price-to-earnings-growth ratio of 1.40 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. As a group, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of analysts have recently weighed in on the stock. Leerink Partners set a $950.00 price target on shares of Eli Lilly and Company in a report on Friday, January 17th. The Goldman Sachs Group upgraded shares of Eli Lilly and Company from a “neutral” rating to a “buy” rating and decreased their price target for the company from $892.00 to $888.00 in a research report on Tuesday. Wells Fargo & Company upped their price target on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Truist Financial increased their price objective on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a research report on Monday, February 3rd. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Friday, February 7th. Two investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,017.67.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.